25 studies found for:    " July 09, 2008":" August 08, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" July 09, 2008":" August 08, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Lovastatin: Immunomodulatory Value Evaluation
Condition: HIV Seropositivity
Interventions: Drug: Lovastatin;   Other: placebo
2 Completed GSK706769/KALETRA Drug-drug Interaction Study
Conditions: Healthy Subjects;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK706769 & KALETRA
3 Completed
Has Results
Safety and Efficacy Study of Switching From Epzicom to Truvada
Condition: HIV Infection
Interventions: Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);   Drug: abacavir (ABC)/lamivudine (3TC)
4 Enrolling by invitation Cerebrospinal Fluid (CSF) Raltegravir Substudy
Condition: HIV Infections
Intervention:
5 Completed Healthy Activities for Prize Incentives
Conditions: Substance Abuse;   HIV Infections
Intervention: Behavioral: contingency management
6 Active, not recruiting Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
Condition: HIV Infections
Interventions: Behavioral: Skills-Building Intervention;   Behavioral: Personal Interview Group
7 Completed
Has Results
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Conditions: Chronic Hepatitis C;   Hepatitis C;   HIV Infections
Interventions: Biological: PEG-IFN alfa-2b;   Drug: RBV
8 Completed Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
Condition: HIV Infections
Intervention: Drug: Addition of raltegravir 800 mg QD to HAART
9 Completed Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families
Condition: HIV Infections
Interventions: Behavioral: Family Centered Advanced Care Planning (FCACP) sessions;   Behavioral: Health education control sessions
10 Completed Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
Condition: HIV Infections
Intervention: Drug: Nevirapine and Efavirenz
11 Completed Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
Condition: HIV Infections
Intervention: Drug: Raltegravir
12 Completed Bone Mineral Density Substudy - An Ancillary Study to MTN-003
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Emtricitabine/tenofovir disoproxil fumarate placebo;   Drug: Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate placebo
13 Completed The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
Conditions: HIV Infection;   Bone Mass
Intervention: Dietary Supplement: cholecalciferol plus calcium carbonate
14 Withdrawn Maraviroc Compassionate Use
Condition: Human Immunodeficiency Virus Type 1
Intervention: Drug: Maraviroc
15 Completed
Has Results
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Condition: Human Immunodeficiency Virus Infections
Interventions: Drug: Efavirenz 600mg;   Drug: Boosted Lexiva
16 Completed
Has Results
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Condition: Human Immunodeficiency Virus (HIV) Infection
Interventions: Drug: Maraviroc;   Drug: Ritonavir;   Drug: Saquinavir
17 Unknown  Social-Psychological Intervention to Improve Adherence to HAART
Conditions: AIDS;   HIV Infections
Interventions: Behavioral: Social-psycho intervention to improve adherence to HAART;   Other: Usual care
18 Active, not recruiting Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART
Conditions: HIV Infections;   Malaria
Interventions: Drug: Lamivudine;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Zidovudine
19 Completed Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
Condition: HIV Infections
Intervention: Drug: Maraviroc
20 Terminated Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy
Conditions: HIV-associated Neuropathy;   Polyneuropathy
Interventions: Drug: SAB378;   Drug: methadone;   Drug: SAB placebo;   Drug: Methadone placebo

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
Indicates status has not been verified in more than two years